- Home
- CLRB
as 06-27-2025 12:30pm EST
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | FLORHAM PARK |
| Market Cap: | 12.5M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Hold | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -23.40 | EPS Growth: | N/A |
| 52 Week Low/High: | $6.50 - $94.50 | Next Earning Date: | 08-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Cellectar Biosciences Inc. News
CLRB Breaking Stock News: Dive into CLRB Ticker-Specific Updates for Smart Investing
MT Newswires
4 days ago
Cellectar Biosciences Signs Isotope Supply Agreement With Nusano
GlobeNewswire
4 days ago
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
GlobeNewswire
6 days ago
Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC)
GlobeNewswire
12 days ago
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
GlobeNewswire
19 days ago
Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma
MT Newswires
25 days ago
Cellectar Biosciences Expects to Raise $2.5 Million via Stock Sale, Warrant Exercise
Zacks
25 days ago
Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year?
GlobeNewswire
25 days ago
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
Compare CLRB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CLRB Cellectar Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.